|
Central neuroblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
The SE fraction demonstrated potent antioxidant capacity, which was significantly higher than the RE or AQ fraction, and also exhibited strong anti-proliferative activity against 11 cancer cell lines including A2780 (ovarian), H460 (lung), A431 (skin), MIA PaCa-2 (pancreas), Du145 (prostate), HT29 (colon), MCF-7 (breast), BE2-C (neuroblastoma), SJ-G2, U87 and SMA (glioblastoma) with low GI<sub>50</sub> values (≤ 2.00 µg/mL).
|
30945069 |
2019 |
|
Central neuroblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Importantly, these saponin-enriched fractions possessed strong anticancer activity in vitro towards a range of cancer cell lines including MIA PaCa-2 (pancreas); A2780 (ovarian); H460 (lung); A431 (skin); Du145 (prostate); HT29 (colon); MCF-7 (breast); SJ-G2, U87, SMA (glioblastoma) and BE2-C (neuroblastoma) at low doses (GI<sub>50</sub> values of 0.36-11.17 µg/mL).
|
30209740 |
2018 |
|
Central neuroblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Antioxidant activity of PTR extract was significantly higher (P < 0.05) than those of four its fractions and ostruthin, a key bioactive compound in the P. trimera, while potent cytotoxic capacity of PTR extract on various cancer cell lines in terms of MiaPaCa-2 (pancreas), HT29 (colon), A2780 (ovarian), H460 (lung), A431 (skin), Du145 (prostate), BE2-C (neuroblastoma), MCF-7 (breast), MCF-10A (normal breast), and U87, SJ-G2, SMA (glioblastoma) was observed with GI<sub>50</sub> values ranging from 15 to 32 μg/ml.
|
28029227 |
2017 |
|
Central neuroblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Dried PTL displayed potent antioxidant activity, while the powdered PTL extract exhibited great anti-proliferative capacity on various cancer cell lines including MiaPaCa-2 (pancreas), HT29 (colon), A2780 (ovarian), H460 (lung), A431 (skin), Du145 (prostate), BE2-C (neuroblastoma), MCF-7 (breast), MCF-10A (normal breast), and U87, SJ-G2, and SMA (glioblastoma).
|
28122160 |
2017 |
|
Central neuroblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Using quantitative RT-qPCR and western blot analyses, we found that the mRNA and protein expression levels of E-cadherin were significantly decreased, whereas that of α-SMA was significantly increased after neuroblastoma cells were treated with different concentrations of TGF-β1.
|
28393230 |
2017 |
|
Central neuroblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
By testing mutiple genes in a model of progressive SMN depletion in NB2a neuroblastoma cells, we obtained evidence that U2-dependent splicing changes occur earlier than U12-dependent ones.
|
25692239 |
2014 |